Callan Capital LLC Sells 228 Shares of Danaher Co. (NYSE:DHR)

Callan Capital LLC cut its position in Danaher Co. (NYSE:DHR) by 14.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,360 shares of the conglomerate’s stock after selling 228 shares during the quarter. Callan Capital LLC’s holdings in Danaher were worth $312,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Redmond Asset Management LLC grew its stake in shares of Danaher by 90.7% in the fourth quarter. Redmond Asset Management LLC now owns 12,737 shares of the conglomerate’s stock valued at $2,924,000 after buying an additional 6,058 shares in the last quarter. Prentice Wealth Management LLC grew its stake in shares of Danaher by 6.5% in the fourth quarter. Prentice Wealth Management LLC now owns 2,834 shares of the conglomerate’s stock valued at $651,000 after buying an additional 172 shares in the last quarter. Ipswich Investment Management Co. Inc. grew its stake in shares of Danaher by 1.4% in the fourth quarter. Ipswich Investment Management Co. Inc. now owns 6,092 shares of the conglomerate’s stock valued at $1,398,000 after buying an additional 84 shares in the last quarter. Greystone Financial Group LLC grew its stake in shares of Danaher by 39.1% in the fourth quarter. Greystone Financial Group LLC now owns 47,810 shares of the conglomerate’s stock valued at $10,975,000 after buying an additional 13,443 shares in the last quarter. Finally, VisionPoint Advisory Group LLC bought a new position in shares of Danaher in the fourth quarter valued at $69,000. 79.05% of the stock is owned by institutional investors.

Insider Activity at Danaher

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of Danaher stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the transaction, the senior vice president now owns 20,230 shares in the company, valued at $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 11.10% of the stock is owned by insiders.

Danaher Stock Up 0.9 %

DHR stock opened at $209.86 on Friday. The company has a market cap of $151.58 billion, a PE ratio of 39.75, a price-to-earnings-growth ratio of 2.66 and a beta of 0.83. The business has a 50-day simple moving average of $226.71 and a 200 day simple moving average of $246.96. Danaher Co. has a 52 week low of $196.80 and a 52 week high of $281.70. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period in the prior year, the firm earned $2.09 earnings per share. Sell-side analysts anticipate that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.61%. This is an increase from Danaher’s previous quarterly dividend of $0.27. Danaher’s payout ratio is 20.45%.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on DHR. Wolfe Research raised Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target for the company in a report on Thursday, October 31st. Wells Fargo & Company cut their price target on Danaher from $280.00 to $240.00 and set an “equal weight” rating for the company in a report on Thursday, January 30th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $277.00 price target (down previously from $299.00) on shares of Danaher in a report on Thursday, January 30th. Jefferies Financial Group cut their price target on Danaher from $285.00 to $260.00 and set a “buy” rating for the company in a report on Wednesday, January 29th. Finally, StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a report on Saturday, December 14th. Seven investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and an average price target of $278.00.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.